- Home
- DMA vs IMRX Comparison
DMA vs IMRX Comparison
Compare DMA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMA | IMRX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.8M | 366.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DMA | IMRX |
|---|---|---|
| Price | $9.02 | $6.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 34.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $1.10 |
| 52 Week High | $8.00 | $10.08 |
Technical Indicators
Market Signals| Indicator | DMA | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.01 | 56.78 |
| Support Level | $8.92 | $5.46 |
| Resistance Level | $9.14 | $6.97 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 69.77 | 86.18 |
Price Performance
Historical ComparisonAbout DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.